Dr. Andrew M. Lowy is a surgical oncologist with a primary interest in cancers of the pancreas, liver and GI tract. He has a specialty interest in the management of patients with metastatic disease to the liver and peritoneum.
Dr. Lowy is recognized worldwide for his expertise in the surgical treatment of pancreatic cancer and for investigating novel cancer treatments which incorporate surgery and chemotherapy to treat patients with advanced cancer that has spread to the abdomen. He has furthered the development of a promising treatment known as the “chemo bath” or heated intraperitoneal chemotherapy (HIPEC), to treat advanced abdominal cancers. During surgery, all visible signs of tumor are removed, and a heated chemotherapy solution is circulated throughout the abdomen for up to 90 minutes. The solution is then removed and the incision closed.
Dr. Lowy serves on the editorial boards of the Journal of Clinical Oncology and the Annals of Surgical Oncology . He also serves as surgical liaison to the Pancreas and Hepatobiliary Committee of the Southwest Oncology Group (SWOG), which is one of the largest National Cancer Institute cooperative groups. Recently, Dr. Lowy was selected to co-chair the National Cancer Institute’s Pancreatic Cancer Task Force which is charged with setting the direction of clinical research in pancreatic cancer in the United States. He has conducted extensive research in gastrointestinal and pancreatic cancer with funding from the National Cancer Institute.
Our work is focused on the study of pancreatic carcinogenesis and therapy. More specifically, we focus on the study of the RON receptor tyrosine kinase and its role in disease pathogenesis and as a potential therapeutic target. We are also extensively involved in model development and testing of novel therapeutics.
- Molecular Biology
- Translational Research
Current Project Titles
- The RON Receptor in Pancreatic Cancer Biology and Therapy
- The iRGD peptide to enhance drug delivery and efficacy in pancreatic cancer